Hamza Hashmi, Myeloma AND Cellular Therapy physician at Memorial Sloan Kettering Cancer Center, shared on X:
“Our study (PA-125) examines the incidence, timing, and clinical impact of CMV reactivation following BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.
An important look at infectious complications in the CAR-T era and potential opportunities to refine monitoring and prevention strategies.
PA-125, Sept 23, 2026, 1200-1300 BST.”
This also can be interesting:
Talquetamab in R/R Multiple Myeloma: Real-World Analysis From the IMWG Immunotherapy Registry
